| 0 (0%) | 07-18 22:20 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.68 | 1-year : | 12.8 |
| Resists | First : | 10 | Second : | 10.96 |
| Pivot price | 9.43  |
|||
| Supports | First : | 8.46 | Second : | 7.03 |
| MAs | MA(5) : | 9.41  |
MA(20) : | 9.36 |
| MA(100) : | 9.99 |
MA(250) : | 16.47 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 49.7 |
D(3) : | 49 |
| RSI | RSI(14): 47.6 |
|||
| 52-week | High : | 34.9 | Low : | 0.56 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LYEL ] has closed above bottom band by 35.5%. Bollinger Bands are 63.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 9.77 - 9.83 | 9.83 - 9.89 |
| Low: | 9.09 - 9.15 | 9.15 - 9.21 |
| Close: | 9.13 - 9.23 | 9.23 - 9.34 |
Fri, 18 Jul 2025
What analysts say about LYEL stock - Rapid wealth creation - Jammu Links News
Mon, 23 Jun 2025
Lyell's Dual-Target CAR T-Cell Therapy Shows Promise in Large B-Cell Lymphoma Treatment - Stock Titan
Tue, 17 Jun 2025
Lyell Immunopharma Stock Soars 23.11% Post Reverse Split - AInvest
Wed, 04 Jun 2025
From Collapse to Comeback: Lyell Immunopharma's Stock Surge Signals Turning Point—Cancer Breakthrough? - FXLeaders
Wed, 04 Jun 2025
Lyell Immunopharma Showcases Next-Gen Cancer Therapies at Major Goldman Sachs Healthcare Event - Stock Titan
Wed, 04 Jun 2025
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 9.57e+006 (%) |
| Held by Institutions | 11.7 (%) |
| Shares Short | 485 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.014e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -801 % |
| Return on Assets (ttm) | 85.6 % |
| Return on Equity (ttm) | -24.5 % |
| Qtrly Rev. Growth | 65000 % |
| Gross Profit (p.s.) | 0.33 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -0.76 |
| Qtrly Earnings Growth | -25 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -175 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 47.84 |
| Price to Cash Flow | -0.11 |
| Dividend | 0 |
| Forward Dividend | 355340 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|